Why the study?
Does ivabradine improve E/e' ratio, 6-minute walking distance, or NT-proBNP in patients with HFpEF in sinus rhythm and heart rate ≥70 bpm?
Population
Patients with heart failure with preserved ejection fraction in sinus rhythm and heart rate of ≥70 b.p.m.
Comparison
Ivabradine vs Placebo
Design
Editorial, randomized, placebo-controlled
Follow-up
over 2 years
Authors
Loading...
The neutral results of the EDIFY trial highlight the pathophysiological heterogeneity of HFpEF and the challenges in translating experimental findings into clinical benefits for this population.
Does ivabradine improve E/e' ratio, 6-minute walking distance, or NT-proBNP in patients with HFpEF in sinus rhythm and heart rate ≥70 bpm?
The neutral results of the EDIFY trial highlight the pathophysiological heterogeneity of HFpEF and the challenges in translating experimental findings into clinical benefits for this population.
Kalogeropoulos et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: